Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

  • Technology appraisal guidance
  • TA1152
  • Published: 
Please note that the appraisal is now due to begin in mid-June 2025. Submissions are expected to be mid-August 2025.

This page was last updated: